Biropepimut-S in phase IIb head and neck cancer trial
Biropepimut-S (GL-0817) is a highly engineered peptide immunomodulator currently in a double blind, placebo controlled clinical trial to prevent recurrence of high risk squamous cell cancer of the oral cavity. Patients with high risk SCCOC have a nearly 70% recurrence rate within 3 years despite surgery, chemoradiotherapy, and a clean CT scan.
Designed in response to previous challenges with clinical immunomodulator studies, biropepimut-S has a number of advanced features that enhance antigen presentation that are not available in any competitive product. These features and a carefully designed trial for a population with low initial tumor burden and high unmet medical need make this an important clinical trial for these patients.